# Advanced Oncotherapy “Derisked and LIGHT system continues to be on track”

- Link: https://www.directorstalkinterviews.com/advanced-oncotherapy-derisked-light-system-continues-track/412737091
- Published: 2017-09-29T07:18:05+01:00
- Author: Giles Arbor

**Advanced Oncotherapy Plc** (LON:AVO), the developer of a next generation proton
therapy system for cancer treatment, announced today its unaudited results for the
six months ended 30 June 2017 and post-period events.

**Highlights:**

· Technological milestones reached with successful integration and testing of proton
source, RFQ and SCDTL significantly de-risking development process

· Progress at the Harley Street site on-track with next stage of sub-structural 
work underway through Deconstruct

· Preparation of two production lines for LIGHT system commercial roll-out

· Additional financing from consortium led by longstanding shareholder AB Segulah,
with long-term financing options under consideration

· Strengthening of scientific and operational expertise

· Shareholder funds of £32.01 million as at 30 June 2017, up from £22.63 million
a year earlier; cash and cash equivalents of £235,437, with a post period end £3.90
million financing from AB Segulah consortium and corporation tax R&D refund of £
3.05 million received

> **Nicolas Serandour, CEO of Advanced Oncotherapy Plc, said:** “Technological development
> of our LIGHT system continues to be on track and, through the successful integration
> and testing of three of the four key structures of LIGHT’s accelerating system,
> we have significantly de-risked the development process and have overcome the 
> greatest technical challenges that this system faces. We are now well positioned
> to accelerate the proton beam through additional SCDTL modules and, beyond that,
> to integrate the fourth key component, the CCLs. The Harley Street site also progresses
> well and our principal contractor Deconstruct remains on schedule.
> “As our technological progress advances we find ourselves in a much stronger position
> as we assess financing options and we have been encouraged by positive feedback.
> We have been able to put financing agreements in place and we hope to provide 
> an update to shareholders on longer-term financing options in due course.
> “We will update shareholders regularly on our future progress and we remain on
> track to build a proton therapy system capable of treating superficial tumours
> by the end of Q3 2018.”

Share on: